Indication: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

Insight:

Dosing: The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. Severe renal impairment or end-stage renal disease take 10 mg once daily.
Dosage form: Tablets 10 mg, 30 mg, and 60 mg
Adverse events (AEs): The most common AEs (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
Mechanism of action: Atogepant is a CGRP receptor antagonist.
Manufacturer: AbbVie

Sources:

QULIPTA-USPI-Clean-01Oct2021-v1.1USPI7094-v1.1PPI7094 (rxabbvie.com)
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine | AbbVie News Center
qulipta image - Google Search